Tag: Biopharma
Ipsen: global licensing agreement with Sutro Biopharma
(CercleFinance.com) – Ipsen announces the signing of an exclusive global licensing agreement with Sutro Biopharma for STRO-003, an antibody-small molecule conjugate (ADC) currently entering its final stages of preclinical development.…
Ipsen: signature of an exclusive agreement with Sutro Biopharma
(AOF) – Ipsen and Sutro Biopharma announced the signing of an exclusive worldwide licensing agreement for STRO-003. Ipsen obtains exclusive global rights to develop and commercialize STRO-003, an antibody-small molecule…
Ipsen: global licensing agreement with Sutro Biopharma – 04/02/2024 at 08:18
(CercleFinance.com) – Ipsen announces the signing of an exclusive global licensing agreement with Sutro Biopharma for STRO-003, an antibody-small molecule conjugate (ADC) currently entering its final stages of preclinical development.…
Johnson & Johnson: Completes the acquisition of Ambrx Biopharma for $2 billion
Read also (CercleFinance.com) – Johnson & Johnson announced that it has successfully completed the acquisition of Ambrx Biopharma, a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to…
Johnson & Johnson buys Ambrx Biopharma – 01/08/2024 at 2:39 p.m.
(AOF) – Johnson & Johnson has entered into a definitive agreement to acquire Ambrx Biopharma, a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop…
First Wave BioPharma soars 163%!
(Boursier.com) — First Wave BioPharma soared this Wednesday on Wall Street by 163% to $9.70, after the group agreed to sell its drug against inflammatory bowel diseases… The clinical-stage biopharmaceutical…
Eli Lilly finalizes the acquisition of Point Biopharma
(AOF) – Eli Lilly today announced the completion of its acquisition of Point Biopharma Global Inc., a biotech company with a pipeline of clinical and preclinical radioligand therapies in development…
Eli Lilly: successful takeover bid for POINT Biopharma Global
(CercleFinance.com) – Eli Lilly announced the success of its acquisition of POINT Biopharma Global, a company with a pipeline of therapies in development for the treatment of cancer. “Next generation…
Eli Lilly down on announcement of Point Biopharma Global takeover, cancer specialist
(AOF) – Eli Lilly (-2.28% to $522.97) is down slightly on Wall Street after the announcement of the takeover of the company Point Biopharma Global. Specializing in the development of…
Biopharma, Samsung’s new frontier
With Samsung Biologics, the Korean conglomerate presents itself as a diligent subcontractor for labs that are increasingly focusing on research. The concrete and glass cubes pile up on the polders…